The Thoc1 Ribonucleoprotein as a Novel Biomarker for Prostate Cancer Treatment Assignment
Technical Report,15 Sep 2014,14 Sep 2018
Health Research, Inc. Buffalo United States
Pagination or Media Count:
Active surveillance AS is an option for men with low risk prostate cancer in order to reduce over treatment, but few men choose itbecause current prognostic indicators are imperfect. The objectives of this research are to test whether pThoc1 can improve the assignmentof prostate cancer patients to therapy. We have completed the goals articulated in the Statement of Work. For specific aim 1, new prostatecancer TMAs have been constructed using specimens from patients treated at Roswell Park. TMAs have been obtained from PCaP. TheseTMAs have been immunostained for pThoc1, and the immunostaining scored. pThoc1 levels did correlate with some clinical variables, butnot others. Immunostaining did not exhibit racial disparities when controlled for disease aggressiveness. For aim 2, prostate cancerspecimens have been obtained from patients enrolled on active surveillance, and retrospective specimens have been obtained from PCaP forpatients who whould have been eligible for active surveillance. These specimens have been immunostained for pThoc1 and pThoc1 levelsanalyzed. pThoc1 levels did correlate with some clinical variables, but not others. For aim 3, ELISA assays for pThoc1 protein and pThoc1autoantibodies have been developed and used to assay serum samples from prostate cancer patients. pThoc1 autoantibody levels areelevated in the serum of prostate cancer patients relative to the serum of healthy control donors. pThoc1 autoantibody levels correlate withsome clinical variables but not others. Overall findings suggest pThoc1 levels tend to correlate with prostate cancer aggressiveness, butthese correlations do not reach statistical significance in some cases.
- Medicine and Medical Research